Bcakground

Interleukin-25 (IL-25) , which is also known as IL-17E, promotes Th2-biased immune responses. This is in contrast to other IL-17 family members > 95%, determined by SDS-PAGE. <0.010 EU per 1 ug of the protein by the LAL method. Measured by its ability to induce CXCL1/GRO alpha secretion in HT-29 human colon adenocarcinoma cells. which promote Th1- and Th17-biased inflammation. IL-25 is an important mediator of allergic reactions and protection against intestinal parasites (1, 2). Mature human IL-25 shares 80% amino acid sequence identity with mouse and rat IL-25 (3, 4). During helminth infections and allergic reactions, IL-25 is locally up-regulated in intestinal and airway epithelial cells, atopic dermatitis skin lesions, and local Th2 cells, eosinophils, and basophils (4-9). It binds to IL-17 RB but also requires IL-17 RA to exert its activity (3, 8, 10). IL-25 acts on a variety of cell types which respond with increased production of Th2 cytokines (e.g. IL-4, IL-5, IL-13) and reduced production of Th1 and Th17 cytokines (e.g. IFN-gamma, IL-12, IL-23, IL-17A, IL-17F) (4-6, 8, 9, 11-15). Airway IL-25 can be activated by MMP-7, a protease that is up-regulated in airway epithelium in response to allergen exposure (16). Cleaved IL-25 shows enhanced binding to IL-17 RB and stronger induction of Th2 cytokines (16). The Th2 cytokines, in turn, trigger expansion of Th2 memory cells and anti-inflammatory M2 macrophages, increased eosinophil mobilization and activation, and dendritic cell migration (4, 6, 9, 13). These actions promote protective anti-helminth immune responses (4, 5) as well as allergic inflammation and airway hyperreactivity (11). The IL-25 induced suppression of Th1 and Th17 cytokines limits Th17 cell expansion and disease pathology in autoimmunity and colitis [12, 14].

Reference

1. Saadoun, D. et al. (2011) Curr. Pharm. Des. 17:3781.

2. Iwakura, Y. et al. (2011) Immunity 34:149.

3. Lee, J. et al. (2001) J. Biol. Chem. 276:1660.

4. Fort, M.M. et al. (2001) Immunity 15:985.

5. Zhao, A. et al. (2010) J. Immunol. 185:6921.

6. Suzukawa, M. et al. (2012) J. Immunol. 189:3641.

7, Corrigan, C.J. et al. (2011) Proc. Natl. Acad. Sci. USA 108:1579.

8. Petersen, B.C. et al. (2012) Nat. Med. 18:751.

9. Wang, Y.-H. et al. (2007) J. Exp. Med. 204:1837.

10. Rickel, E.A. et al. (2008) J. Immunol. 181:4299.

11. Hurst, S.D. et al. (2002) J. Immunol. 169:443.

12. Kleinschek, M.A. et al. (2007) J. Exp. Med. 204:161.

13. Cao, Q. et al. (2011) J. Am. Soc. Nephrol. 22:1229.

14. Stock, P. et al. (2009) J. Immunol. 182:5116.

Specifications

Synonyms	Human IL25; interleukin-25; IL25; IL-25; IL17E; IL-17E; interleukin-17E;
Accession #	Q9H293
Source	Human embryonic kidney cell, HEK293-derived human IL-25 protein
Source	Tyr33-Gly177
Predicted Moleucular weight	16.7 kDa

Components and Storage

Formulation	Solution protein
	Dissolved in sterile PBS buffer
	This solution can be diluted into other aqueous buffers. Centrifuge the vial prior to opening.
Storage and Stability	Avoid repeated freeze-thaw cycles.
	It is recommended that the protein be aliquoted for optimal storage.
	12 months from date of receipt, -20 to -70 °C as supplied.
Shipping	Shipping with dry ice.

Quality

Purity	> 95%, determined by SDS-PAGE.
Endotoxin Level	<0.010 EU per 1 ug of the protein by the LAL method.
Activity	Measured by its ability to induce CXCL1/GRO alpha secretion in HT-29 human colon adenocarcinoma cells.
Activity	The EC50 for this effect is 0.2-1.2 ng/mL.

SDS-PAGE

Gel filtration

Bioactivity

Documents

Human IL25